Keros Therapeutics: Analysts Project Substantial Growth Potential

Keros Therapeutics Inc (NASDAQ: KROS) is drawing significant market attention as CEO Jasbir Seehra prepares to present at the Wells Fargo Healthcare Conference. Trading at approximately $15.72 per share, the biotechnology firm has become a focal point for analysts who identify considerable upside in its equity valuation.

The company’s most recent quarterly report reveals a dramatic financial improvement. Keros Therapeutics reported a net profit of $148.5 million for Q1 2025, a stark contrast to the $43.1 million loss recorded during the same period last year. This impressive turnaround is further strengthened by a substantial cash reserve of $720.5 million in liquid assets. This financial security provides operational funding through 2029, a rare advantage in the capital-intensive biotechnology sector.

Strong Analyst Conviction and Price Read more...